Welcome to the e-CCO Library!

P436: Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
Year: 2022
Source: ECCO'22
Authors: Dipasquale, V.(1);Pellegrino, S.(1);Cucinotta, U.(1);Citrano, M.(2);Graziano, F.(2);Cappello, M.(3);Busacca, A.(3);Orlando, A.(4);Accomando, S.(5);Romano, C.(1);
Created: Friday, 11 February 2022, 3:52 PM
P436: Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn's disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schreiber, S.W.(1)*;Lee, S.(2);van der Woude , C.J.(3);Marín-Jiménez , I.(4);Wolf, D.(5);Schnoy, E.(6);Salzberg , B.(7);Busse , C.(8);Nazar, M.(9);Langholff, W.(10);Borghorst, S.(11);Gasink, C.(8);Baker, T.(12);Godwin, B.(8);Feagan, B.(13);
Created: Friday, 14 July 2023, 11:05 AM
P436: Ileal pouch-anal anastomosis with fluorescence angiography: Initial experience and potential application
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Spinelli1*, P.G. Kotze2, M. Carvello1, F. Di Candido1, N. Buchs3, F. Ris4

Created: Thursday, 21 February 2019, 9:14 AM
P436: Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Jimenez M.*1, Sierra-Ausin M.1, Cano N.1, Suarez P.1, Fernandez-Gundin M.1, Saez-Villafañe M.2, Monteserin L.1, Molina G.1, Reyes N.1, Viso D.1, Jorquera F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P436: SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
Year: 2021
Source: ECCO'21 Virtual
Authors: Macaluso, F.(1);Cappello, M.(2);Busacca, A.(2);Fries, W.(3);Viola, A.(3);Costantino, G.(3);Magnano, A.(4);Vinci, E.(4);Ferracane, C.(4);Privitera, A.C.(5);Piccillo, G.(5);Belluardo, N.(6);Giangreco, E.(6);Romano, C.(7);Citrano, M.(8);Graziano, F.(8);Garufi, S.(9);Bertolami, C.(10);Scrivo, B.(1);Renna, S.(1);Casà, A.(1);Rizzuto, G.(1);Ventimiglia, M.(1);Orlando, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P437 Anti-TNF α antibodies in patients with inflammatory bowel disease naive to anti-TNF therapy treated with biosimilar infliximab (CT-P13): a prospective single-centre real-life study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Filip1, A. Pękala1, S. Jarmakiewicz-Czaja2

Created: Thursday, 30 January 2020, 10:12 AM
P437: Autologous hematopoietic stem cell transplantation for refractory Crohn's disease: predictive factors of relapse
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lόpez García A.*1, Rovira M.2, Jauregui Amezaga A.1, Marin P.3, Barastegui R.1, Salas A.1, Feu F.1, Elizalde J.1, Fernández-Avilés F.2, Martínez C.4, Gutierrez G.2, Rosiñol L.2, Carreras E.2, Urbano A.2, Lozano M.3, Cid J.3, Suárez-Lledό M.2, Masamunt M.C.1, Comas D.1, Giner A.1, Gallego M.1, Alfaro I.1, Ordás I.1, Panés J.1, Ricart E.1

Created: Wednesday, 20 February 2019, 10:36 AM
P437: Confidence, acceptance, and friendship: the 3 winners at Camp Purple Live 2015
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. McCombie*1, 2, R. Gearry3, R. Lopez4, S. Lönnfors5, A. Day4

Created: Friday, 22 February 2019, 9:49 AM
P437: Early therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome .
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Carrillo Palau, M.(1)*;Alonso-Abreu, I.(1);Morant, A.(1);Vera, B.(1);Vela , M.(2);Ramos, L.(1);Franco, A.(3);Reygosa, C.(1);Barrios, Y.(3);Medina Chico, J.S.(1);Globio, V.(4);Hernández-Perez, A.(1);Jiménez, A.(5);Hernández-Guerra, M.(1);
Created: Friday, 14 July 2023, 11:05 AM
P437: Higher adalimumab maintenance regimens are more effective than standard maintenance doses in Crohn’s disease patients who have failed infliximab
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Narula1*, T. Greener2, K. Boland2, A.H. Steinhart2, M. Silverberg2

Created: Thursday, 21 February 2019, 9:14 AM
P437: Hyperbaric oxygen therapy for Inflammatory Bowel Disease – a systematic review
Year: 2021
Source: ECCO'21 Virtual
Authors: Meima - van Praag, E.(1);Lansdorp, C.(2);Smeekes, G.(1);Gecse, K.(3);van Hulst, R.(2);Buskens, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P437: Reoperations and long-term survival of Kock’s continent ileostomy in Inflammatory bowel disease patients: a population based national cohort study from Sweden.
Year: 2022
Source: ECCO'22
Authors: Risto, A.(1);Andersson, R.E.(1);Landerholm, K.(1);Bengtsson, J.(2);Block, M.(2);Myrelid, P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P437: Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Calafat*1, M. Mañosa1,2, J. Panes2,3, P. Nos2,4, E. Iglesias5, I. Vera6, A. López-Sanromán7, J. Guardiola8, C. Taxonera9, M. Mínguez10, M. D. Martín11, L. de Castro12, S. Riestra13, M. Rivero14, E. García-Planella15, X. Calvet2,16, S. García-López17, M. Andreu18, F. Gomollón19, J. Barrio20, M. Esteve2,21, A. Rodríguez22, J. P. Gisbert2,23, A. Gutierrez24, J. Hinojosa25, F. Argüelles26, D. Busquets27, L. Bujanda28, J. Lázaro29, B. Sicilia30, O. Merino31, P. Martínez32, F. Bermejo33, R. Lorente34, M. Barreiro-de-Acosta35, C. Rodríguez36, M. Fe37, M. Piqueras38, P. Romero39, E. Rodríguez40, Ó. Roncero41, J. Llaó42, G. Alcaín43, J. Riera44, M. Sierra45, L. I. Fdez. Salazar46, V. Jair47, M. Navarro48, M. A. Montoro49, C. Muñoz, A. J. Lucendo, M. Van Domselaar, I. Moraleja, J. M. Huguet, L. Ramos, P. Ramírez, P. Almeda, R. Pajares, S. Khorrami, R. E. Madrigal, E. Sesé, A. M. Trapero, J. Legido, Á. Abad, F. Cañete1,2, E. Cabré1,2, E. Domènech1,2

Created: Friday, 22 February 2019, 9:41 AM
P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Barberio1, F. Zingone1, A. Ferronato2, A. Buda3, P. Melatti1, A. Gubbiotti1, D. Massimi1, C. Casadei1, L. Cingolani4, E.V. Savarino1

Created: Thursday, 30 January 2020, 10:12 AM
P438: Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Van de Vondel S.*1, Baert F.2, Reenaers C.3, Bossuyt P.4, Hindryckx P.5, Vanden Branden S.6, Amininejad L.7, Dewint P.8, Rahier J.F.9, Ferrante M.1 Belgian IBD Research and Development

Created: Wednesday, 20 February 2019, 10:36 AM
P438: Efficacy and safety of ustekinumab for Ulcerative Colitis through 4 years in Asian patients: Final results from the sub-population of UNIFI long-term extension
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hisamatsu, T.(1)*;Kim, H.J.(2);Motoya, S.(3);Suzuki, Y.(4);Ohnishi, Y.(5);Marano, C.(6);Imai, Y.(7);Saadoun, C.(8);Zhuo, J.(9);Kawamura, S.(8);
Created: Friday, 14 July 2023, 11:05 AM
P438: Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are rare but insidious adverse events: data from a large single-centre cohort
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. S. Macaluso*1, C. Sapienza1, M. Ventimiglia1, M. Cottone1, A. Orlando1

Created: Friday, 22 February 2019, 9:41 AM
P438: Maladaptive decision-making is associated with psychological morbidity in people with Inflammatory Bowel Disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Grinsted Tate, L.(1);Johnson, L.(1);Jones, G.(2);Lobo, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P438: Reinduction with ustekinumab in Crohn’s disease patients with a loss of response to treatment
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Heron1*, S. Restellini1,2, T. Bessissow1, C. Lemieux1, P. Lakatos1, G. Wild1, E. Seidman1, A. Bitton1, W. Afif1

Created: Thursday, 21 February 2019, 9:14 AM
P438: The Efficacy and Safety of ustekinumab Therapy in refractory Inflammatory Bowel Disease (IBD) patients with co-morbidities and old age.
Year: 2022
Source: ECCO'22
Authors: Davies, B.(1);Lodhia, M.(1);Abdalla, B.(1);Gupta, V.(1);
Created: Friday, 11 February 2022, 3:52 PM